MacroGenics is set to receive a $15 million milestone payment from Gilead, which is using the company’s two bispecific antibody platforms in a research program. The program will be led by MacroGenics and funded by Gilead.
The original partnership was struck in October 2022. MacroGenics is…
Click here to view original post
